EA201691189A1 - Спиро-оксазолоны - Google Patents
Спиро-оксазолоныInfo
- Publication number
- EA201691189A1 EA201691189A1 EA201691189A EA201691189A EA201691189A1 EA 201691189 A1 EA201691189 A1 EA 201691189A1 EA 201691189 A EA201691189 A EA 201691189A EA 201691189 A EA201691189 A EA 201691189A EA 201691189 A1 EA201691189 A1 EA 201691189A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- receptors
- disorders
- present
- spiro
- oxasolones
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
В настоящем изобретении предложены спиро-оксазолоны, которые действуют в качестве модуляторов рецепторов V1a, и, в частности, антагонистов рецепторов V1a, их производству, содержащим их фармацевтическим композициям и их применению в качестве лекарственных средств. Соединения настоящего изобретения применяют в качестве терапевтических средств периферического и центрального действия при нарушении секреции вазопрессина, тревожности, депрессивных расстройствах, обсессивно-компульсивном расстройстве, расстройствах аутистического спектра, шизофрении, агрессивном поведении и нарушениях сна со сдвигом фазы, в частности синдрома смены часовых поясов.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13198604 | 2013-12-19 | ||
| PCT/EP2014/077858 WO2015091411A1 (en) | 2013-12-19 | 2014-12-16 | Spiro-oxazolones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201691189A1 true EA201691189A1 (ru) | 2016-10-31 |
| EA029167B1 EA029167B1 (ru) | 2018-02-28 |
Family
ID=49876427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201691189A EA029167B1 (ru) | 2013-12-19 | 2014-12-16 | Спиро-оксазолоны |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US10479796B2 (ru) |
| EP (1) | EP3083633B1 (ru) |
| JP (1) | JP6530407B2 (ru) |
| KR (1) | KR102353431B1 (ru) |
| CN (1) | CN105814062B (ru) |
| AR (1) | AR098783A1 (ru) |
| AU (1) | AU2014364729B2 (ru) |
| BR (1) | BR112016013058B1 (ru) |
| CA (1) | CA2932063C (ru) |
| CL (1) | CL2016001495A1 (ru) |
| CR (1) | CR20160215A (ru) |
| DK (1) | DK3083633T3 (ru) |
| EA (1) | EA029167B1 (ru) |
| ES (1) | ES2657994T3 (ru) |
| HK (1) | HK1223920A1 (ru) |
| HR (1) | HRP20180160T1 (ru) |
| HU (1) | HUE036203T2 (ru) |
| IL (1) | IL245464B (ru) |
| LT (1) | LT3083633T (ru) |
| MA (1) | MA39139B1 (ru) |
| MX (1) | MX370663B (ru) |
| MY (1) | MY177313A (ru) |
| NO (1) | NO3083633T3 (ru) |
| NZ (1) | NZ719765A (ru) |
| PE (1) | PE20160864A1 (ru) |
| PH (1) | PH12016500919A1 (ru) |
| PL (1) | PL3083633T3 (ru) |
| PT (1) | PT3083633T (ru) |
| RS (1) | RS56791B1 (ru) |
| SG (1) | SG11201604915PA (ru) |
| SI (1) | SI3083633T1 (ru) |
| TW (1) | TWI548639B (ru) |
| UA (1) | UA117273C2 (ru) |
| WO (1) | WO2015091411A1 (ru) |
| ZA (1) | ZA201603221B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201600522A (zh) * | 2014-02-20 | 2016-01-01 | 赫孚孟拉羅股份公司 | 螺－唑酮 |
| WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
| AR127706A1 (es) | 2021-11-19 | 2024-02-21 | Hoffmann La Roche | Síntesis de 2-(7,7-dimetil-1h,7h-espiro[furo[3,4-b]piridin-5,4-piperidin]-1-il)-1,3-dihidro-4h-espiro[inden-2,5-[1,3]oxazol]-4-ona |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1566384B1 (en) * | 2002-11-29 | 2009-06-17 | Banyu Pharmaceutical Co., Ltd. | Novel azole derivatives |
| US7351706B2 (en) | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
| DE602007006989D1 (en) * | 2006-12-07 | 2010-07-15 | Hoffmann La Roche | Spiropiperidinderivate |
| CA2674518A1 (en) * | 2006-12-22 | 2008-07-03 | F.Hoffmann-La Roche Ag | Spiro-piperidine derivatives |
| ATE536356T1 (de) * | 2007-01-12 | 2011-12-15 | Hoffmann La Roche | Spiropiperidin-glycinamid-derivate |
| WO2010054961A1 (en) * | 2008-11-13 | 2010-05-20 | F. Hoffmann-La Roche Ag | Spiro-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulenes |
-
2014
- 2014-12-16 BR BR112016013058-8A patent/BR112016013058B1/pt active IP Right Grant
- 2014-12-16 RS RS20180097A patent/RS56791B1/sr unknown
- 2014-12-16 KR KR1020167019366A patent/KR102353431B1/ko active IP Right Grant
- 2014-12-16 PL PL14815318T patent/PL3083633T3/pl unknown
- 2014-12-16 EP EP14815318.2A patent/EP3083633B1/en active Active
- 2014-12-16 PT PT148153182T patent/PT3083633T/pt unknown
- 2014-12-16 UA UAA201607813A patent/UA117273C2/uk unknown
- 2014-12-16 SG SG11201604915PA patent/SG11201604915PA/en unknown
- 2014-12-16 AU AU2014364729A patent/AU2014364729B2/en active Active
- 2014-12-16 PE PE2016000722A patent/PE20160864A1/es unknown
- 2014-12-16 MY MYPI2016001019A patent/MY177313A/en unknown
- 2014-12-16 CA CA2932063A patent/CA2932063C/en active Active
- 2014-12-16 ES ES14815318.2T patent/ES2657994T3/es active Active
- 2014-12-16 JP JP2016541359A patent/JP6530407B2/ja active Active
- 2014-12-16 MX MX2016007809A patent/MX370663B/es active IP Right Grant
- 2014-12-16 NO NO14815318A patent/NO3083633T3/no unknown
- 2014-12-16 SI SI201430574T patent/SI3083633T1/en unknown
- 2014-12-16 HU HUE14815318A patent/HUE036203T2/hu unknown
- 2014-12-16 DK DK14815318.2T patent/DK3083633T3/da active
- 2014-12-16 WO PCT/EP2014/077858 patent/WO2015091411A1/en active Application Filing
- 2014-12-16 CN CN201480067988.1A patent/CN105814062B/zh active Active
- 2014-12-16 LT LTEP14815318.2T patent/LT3083633T/lt unknown
- 2014-12-16 NZ NZ719765A patent/NZ719765A/en unknown
- 2014-12-16 EA EA201691189A patent/EA029167B1/ru not_active IP Right Cessation
- 2014-12-16 MA MA39139A patent/MA39139B1/fr unknown
- 2014-12-17 AR ARP140104703A patent/AR098783A1/es active IP Right Grant
- 2014-12-18 TW TW103144383A patent/TWI548639B/zh active
-
2016
- 2016-05-03 IL IL24546416A patent/IL245464B/en active IP Right Grant
- 2016-05-05 CR CR20160215A patent/CR20160215A/es unknown
- 2016-05-12 ZA ZA2016/03221A patent/ZA201603221B/en unknown
- 2016-05-18 PH PH12016500919A patent/PH12016500919A1/en unknown
- 2016-06-06 US US15/174,674 patent/US10479796B2/en active Active
- 2016-06-15 CL CL2016001495A patent/CL2016001495A1/es unknown
- 2016-10-19 HK HK16112054.0A patent/HK1223920A1/zh unknown
-
2018
- 2018-01-29 HR HRP20180160TT patent/HRP20180160T1/hr unknown
-
2019
- 2019-10-08 US US16/596,293 patent/US11578077B2/en active Active
-
2022
- 2022-11-29 US US18/059,554 patent/US20230106150A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122796T1 (el) | Βελτιωμενες φαρμακοτεχνικες μορφες αδενοϊων | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| EA201690629A1 (ru) | Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip | |
| MX367420B (es) | Metodos y composiciones para inhibicion de proteinas que contienen bromodominio. | |
| PH12016501192A1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| EA201400833A1 (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| EA201300388A1 (ru) | Соединения замещенного бензамида | |
| MA42919A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| EA201790785A1 (ru) | Производные тетрагидроизохинолина | |
| EA201600124A1 (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| EA201591648A1 (ru) | Бензимидазол-2-ил-пиримидиновые модуляторы рецептора гистамина h4 | |
| MX2016004540A (es) | Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). | |
| UA116889C2 (uk) | Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc) | |
| EA201490519A1 (ru) | Селективные модуляторы рецепторов андрогенов | |
| PH12016500124A1 (en) | Via antagonists to treat phase shift sleep disorders | |
| BR112013026851A2 (pt) | Composição de polipropileno, processo de produção de uma composição de polipropileno, material e uso de uma composição | |
| EA201691189A1 (ru) | Спиро-оксазолоны | |
| CL2015000580A1 (es) | Compuestos derivados de pirazol carboxamida, moduladores taar; composicion farmaceutica; proceso para obtenerlos; y su uso para el tratamiento terapeutico o profilactico de la depresion, trastornos de ansiedad, trastorno de hiperactividad con deficit de atencion, trastornos psicoticos, esquizofrenia y parkinson, entre otros. | |
| NZ702239A (en) | Heteroaryl compounds and methods of use thereof | |
| MX366607B (es) | Espiro-oxazolonas. | |
| EA201790919A1 (ru) | Спиротиазолоны | |
| UY34752A (es) | Agentes para el control de la chinche del eucalipto | |
| EA201491769A1 (ru) | Фармацевтическая композиция с фиксированной дозой, содержащая мометазон и азеластин | |
| EA201591770A1 (ru) | Таксоиды - принцип очистки для жидких наполнителей | |
| EA201491291A1 (ru) | АГОНИСТЫ mGlu 2/3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |